Study of AZD2811 + Durvalumab in ES-SCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Combining Epigenetic And Immune Therapy to Beat Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
- Status
- RECRUITING
- Phase
- PHASE1
A Real-world Study of Durvalumab for Lung Cancer in China
- Status
- UNKNOWN
- Phase
- N/A
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom
- Status
- COMPLETED
- Phase
- N/A
Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
- Status
- RECRUITING
- Phase
- PHASE2
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
- Status
- COMPLETED
- Phase
- PHASE3
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
- Status
- WITHDRAWN
- Phase
- PHASE2
A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1